Boehringer Blood Thinner Linked To Heart Attacks: Study

Law360, New York (January 10, 2012, 7:15 PM EST) -- A new study released Monday found that Boehringer Ingelheim GmbH's Pradaxa carries an increased risk of heart attack compared with other anti-coagulants, spurring at least one plaintiffs' firm to put out a feeler for potential clients who took the drug.

The study in the Archives of Internal Medicine examined seven trials with 30,514 participants, finding a “small increased” heart attack risk with dabigatran, the main ingredient in Pradaxa, compared with the blood thinners warfarin or enoxaparin, or a placebo.

Out of 20,000 patients who took dabigatran,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.